Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab ± investigational agents in BCG-unresponsive high-risk NMIBC
2022-502526-41-00Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Mar 2016
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 18
01
Overview
Phase 2, open-label trial of pembrolizumab, vibostolimab + pembrolizumab and favezelimab + pembrolizumab in non-muscle-invasive bladder cancer (NMIBC) (2 cohorts), sponsored by Merck & Co. Primary endpoints: Cohort A: Complete Response (CR) Rate of High-Risk Non-Muscle Invasive Bladder Cancer (NMIBC), Cohort B: 12-month Disease-Free Survival (DFS) Rate of High-Risk NMIBC and 2 more. Started Mar 2016; status: completed.
02
Drugs
03
Conditions
non-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on 2022-502526-41-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502526-41-00.